Article Type
Changed
Wed, 03/23/2022 - 20:17

Key clinical point: Atopic dermatitis (AD) was associated with an increased burden of a wide range of psychiatric, dermatologic, and extracutaneous comorbidities, increased awareness of which could help better patient management.

Major finding: Compared with control participants, adults with AD were at an increased risk for psychiatric disorders, such as anxiety (odds ratio [OR] 1.44) and obsessive-compulsive disorder (OR 2.01); autoimmune diseases, such as alopecia areata (OR 6.01) and vitiligo (OR 4.44); dermatologic problems, such as cellulitis (OR 2.52); and systemic conditions, such as lymphoid malignancy (OR 1.91), atherosclerosis (OR 1.69), and metabolic syndrome (OR 1.47; all P < .001).

Study details: Findings are a retrospective analysis of 39,779 patients with AD, who were matched with 353,743 control participants from the general population.

Disclosures: The corresponding author Dr. Kwatra received funding from Pfizer and declared serving as an advisory board member, consultant, and investigator for several sources.

Source: Roh YS et al. J Am Acad Dermatol. 2021 (Nov 17). Doi: 10.1016/j.jaad.2021.11.014.

Publications
Topics
Sections

Key clinical point: Atopic dermatitis (AD) was associated with an increased burden of a wide range of psychiatric, dermatologic, and extracutaneous comorbidities, increased awareness of which could help better patient management.

Major finding: Compared with control participants, adults with AD were at an increased risk for psychiatric disorders, such as anxiety (odds ratio [OR] 1.44) and obsessive-compulsive disorder (OR 2.01); autoimmune diseases, such as alopecia areata (OR 6.01) and vitiligo (OR 4.44); dermatologic problems, such as cellulitis (OR 2.52); and systemic conditions, such as lymphoid malignancy (OR 1.91), atherosclerosis (OR 1.69), and metabolic syndrome (OR 1.47; all P < .001).

Study details: Findings are a retrospective analysis of 39,779 patients with AD, who were matched with 353,743 control participants from the general population.

Disclosures: The corresponding author Dr. Kwatra received funding from Pfizer and declared serving as an advisory board member, consultant, and investigator for several sources.

Source: Roh YS et al. J Am Acad Dermatol. 2021 (Nov 17). Doi: 10.1016/j.jaad.2021.11.014.

Key clinical point: Atopic dermatitis (AD) was associated with an increased burden of a wide range of psychiatric, dermatologic, and extracutaneous comorbidities, increased awareness of which could help better patient management.

Major finding: Compared with control participants, adults with AD were at an increased risk for psychiatric disorders, such as anxiety (odds ratio [OR] 1.44) and obsessive-compulsive disorder (OR 2.01); autoimmune diseases, such as alopecia areata (OR 6.01) and vitiligo (OR 4.44); dermatologic problems, such as cellulitis (OR 2.52); and systemic conditions, such as lymphoid malignancy (OR 1.91), atherosclerosis (OR 1.69), and metabolic syndrome (OR 1.47; all P < .001).

Study details: Findings are a retrospective analysis of 39,779 patients with AD, who were matched with 353,743 control participants from the general population.

Disclosures: The corresponding author Dr. Kwatra received funding from Pfizer and declared serving as an advisory board member, consultant, and investigator for several sources.

Source: Roh YS et al. J Am Acad Dermatol. 2021 (Nov 17). Doi: 10.1016/j.jaad.2021.11.014.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis January 2022
Gate On Date
Sat, 12/25/2021 - 15:15
Un-Gate On Date
Sat, 12/25/2021 - 15:15
Use ProPublica
CFC Schedule Remove Status
Sat, 12/25/2021 - 15:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]